Navigation Links
Studies Show Excellent Outcomes With Strut-Based Breast Brachytherapy
Date:9/23/2013

ALISO VIEJO, Calif., Sept. 23, 2013 /PRNewswire/ -- Cianna Medical, Inc., a women's health company, today announced results of two new studies showing excellent longer-term outcomes with the SAVI® breast brachytherapy applicator, including low recurrence rates, few toxicities, excellent cosmetic outcomes and high rates of survival. SAVI is a strut-based applicator that delivers accelerated partial breast irradiation (APBI), a 5-day course of targeted radiation for early-stage breast cancer.

(Logo: http://photos.prnewswire.com/prnh/20130923/LA83795LOGO)

Data came from the SAVI Collaborative Research Group (SCRG), which studies the long-term outcomes of women treated with ABPI with SAVI and will be presented as posters at the 55th annual meeting of the American Society for Radiation Oncology (ASTRO), September 22-25, 2013, in Atlanta.

"APBI is an accepted treatment for certain women with early-stage breast cancer, with multiple Phase II and III clinical trials demonstrating its efficacy and safety," said Robert Kuske, MD, co-principal investigator of the SCRG and a radiation oncologist at Arizona Breast Cancer Specialists, Phoenix, Ariz. "This new data further validates strut-based brachytherapy as a safe and effective method for delivering partial breast radiation, which means more women will have access to a treatment that delivers highly targeted radiation with much greater convenience."

The first study detailed outcomes with the most mature follow-up of patients treated with strut-based APBI. The multi-institutional study examined 101 patients with a median follow-up of 4.5 years, reporting very low toxicity rates (< 3%) and excellent local control (2%). Overall and cause-specific actuarial survival rates were 100%.

"On longer follow-up, strut-based brachytherapy continually meets the standards we look for in a safe and effective breast cancer treatment – very high rates of survival and local control, few toxicities and excellent cosmetic outcomes," said lead author Catheryn Yashar, MD, a radiation oncologist at UC San Diego's Moores Cancer Center, La Jolla, Calif., and co-principal investigator of the SCRG.

A second study of a larger population (576 patients) with a median follow-up of 3 years reported similarly favorable results, including low toxicities and a local recurrence rate of less than 2.5%. Overall and cause-specific actuarial survival rates were 99.5%.

"Strut-based brachytherapy makes it possible to approach breast cancer treatment in a more sophisticated way. SAVI's unique design enables physicians to customize radiation specific to the patient, allowing us to offer a very personalized level of care," said lead author Robert Hong, MD, a radiation oncologist at Virginia Hospital Center, Arlington, Va.

Strut-based APBI is part of breast conservation therapy (BCT), which consists of a lumpectomy followed by radiation therapy. Traditionally, radiation consisted of whole breast irradiation (WBI), which requires 6-7 weeks of daily treatments. APBI delivers radiation to the area immediately surrounding the lumpectomy cavity, enabling treatment to be completed in as little as 5 days and sparing healthy tissue from unnecessary radiation. The strut-based, open architecture design of SAVI allows physicians to sculpt radiation based on patient-specific anatomy, which increases the number of women eligible for APBI.

About Cianna Medical, Inc.

Cianna Medical, Inc. is a medical device company focused on women's health and dedicated to the innovative treatment of early-stage breast cancer. The company manufactures and markets the SAVI breast brachytherapy applicator, for the delivery of radiation after lumpectomy surgery. The applicator allows precise sculpting of the radiation dose, and is designed to make the benefits of accelerated partial breast irradiation available to a greater number of women.

For more information, call (toll-free) 866-920-9444 or visit www.ciannamedical.com.


'/>"/>
SOURCE Cianna Medical, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. JDRF Announces Research Collaboration with Dexcom, Inc. to Develop "Smart Transmitter" Technology to Accelerate Artificial Pancreas Studies
2. First assessment of individual RLS domains in new post-hoc analyses of Neupro® studies
3. Southern Research Signs Agreement with Apath, LLC to Conduct Preclinical Studies with Virus-Based HCV Screenings
4. Unigenes Potent, Anorexigenic Peptide, UGP281, Demonstrates Dramatic Dose Dependent Reductions in Food Intake with Subsequent Significant Body Weight Reduction in Preclinical Studies
5. Agendia Announces Nine Studies in Breast and Colon Cancer for Presentation at 2012 Annual Meeting of the American Society of Clinical Oncology (ASCO)
6. Lilly and Boehringer Ingelheim Present Data at the 72nd American Diabetes Association Scientific Sessions® from Phase II Studies Comparing Investigational Novel Basal Insulin to Insulin Glargine
7. Abbott Presents Results of Clinical Studies Evaluating Its Investigational Treatment for Advanced Parkinsons Disease
8. Lexicon Announces Publication of Results of Two Studies of LX4211 in Patients with Type 2 Diabetes in the Journal Clinical Pharmacology & Therapeutics
9. Pulse Oximetry Screening Hailed as the New Milestone to Combat Critical Congenital Heart Disease - Signal Extraction Technology Leading the Way in Large, Independent Clinical Studies
10. Omeros Successfully Completes Preclinical Studies of OMS824 for Schizophrenia and Phase 1 Clinical Trial Preparations Underway
11. Pressure BioSciences Patented PCT Platform Shown to Significantly Improve Protein and DNA Detection in Multiple Studies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/2/2016)... , May 2, 2016  Celsion Corporation (NASDAQ: ... company, today announced data from the first cohort ... clinical trial (the OVATION Study) combining GEN-1, the ... for the treatment of newly-diagnosed patients with advanced ... by interval debulking surgery.  In the first three ...
(Date:4/29/2016)... 2016 Interview ... Sanofi, leader mondial et diversifié ... pour le premier trimestre 2016. Le ... commente les résultats du premier trimestre ... le reste de l,année. ...
(Date:4/28/2016)... Research and Markets has announced the addition ... report to their offering.      (Logo: ... plastic surgery products market is expected to grow at ... ,The growing adoption of laser in aesthetics is another ... Lasers are used to treat a broad range of ...
Breaking Medicine Technology:
(Date:5/2/2016)... ... May 02, 2016 , ... Those who ... center can find some useful information in a new video released by Serenity ... video, which can be viewed on the Serenity Recovery YouTube channel, examines various ...
(Date:5/2/2016)... ... 2016 , ... As directed by its board of directors during its April ... to allow certified nurse practitioners (CNP) to practice to the full scope of their ... for three years and 3,600 hours. , In addition, HAP supports CNPs who are ...
(Date:5/2/2016)... ... May 02, 2016 , ... The Civilian Corps of ... honor the civilian nurses that care for its uniformed service members, the retired service ... in 1974 designating May 6th through May 12th National Nurses Week. It acknowledges the ...
(Date:5/2/2016)... ... 2016 , ... “Engineering Bubbles,” an oil painting submitted by Canadian radiology resident ... recently at the Annual Meeting in Los Angeles. The first annual art forum was ... Annual Meeting attendees. , “Through art I hope to educate people about radiology ...
(Date:5/2/2016)... ... May 02, 2016 , ... WestHarbor Growth Partners, a growth, ... release of Grow Healthy Vending’s newly revamped brand campaign. Grow Healthy Vending ... vending providers in North America with locations across the United States as well ...
Breaking Medicine News(10 mins):